Startup Magenta Therapeutics licences technologies from Harvard, MGH, and Boston Children's that could transform treatment of blood diseases and immune disorders
Harvard University has completed a license agreement with Magenta Therapeutics, a new startup company launched in Cambridge, for a portfolio of technologies with the potential to transform blood stem cell transplants from a “treatment of last resort” into a safer, more efficient therapy for patients with blood diseases...
Immature (undifferentiated) cells are on the left panel and cells that have differentiated in response to treatment with brequinar are on the right panel. Photo courtesy of Scadden Lab.
Simple compound could provide first new therapy for AML in...
Two HSCI Principal Faculty members, Leonard Zon, MD, and Fernando Camargo, PhD, have received awards for their outstanding contribution to the field of stem cell science from the International Society for Stem Cell Research (ISSCR),...